Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 3Thoracic 1NET 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1

Conditions

Neuroendocrine Tumors 1Multiple Endocrine Neoplasia 1

Interventions

Everolimus 27pembrolizumab 25Temozolomide 24lutetium Lu 177 dotatate 22Nivolumab 18Magnetic Resonance Spectroscopy 18lenvatinib 17cabozantinib 17Cisplatin 16Sunitinib 15Capecitabine 14Bevacizumab 14Specimen Handling 12Sorafenib 12trametinib 10Ipilimumab 10Etoposide 10pasireotide 9dabrafenib 9Paclitaxel 9Carboplatin 8pazopanib 7lanreotide 7Octreotide 7Fluorodeoxyglucose F18 7anlotinib 6Irinotecan 6Injections 6Doxorubicin 6surufatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leflunomide × Endocrine × Clear all
NCT06540937 2024-08-07

Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
50 enrolled
EndocrineNET

Multiple Endocrine Neoplasia, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡